ClinicalTrials.gg
CompletedNCT04400071Updated Oct 28, 2026Results posted

Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

An interventional study of Active Music Engagement and Audio Storybooks in Acute Lymphoblastic Leukemia, Pediatric and Pediatric Cancer, sponsored by Indiana University. Completed at 4 sites in United States. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Indiana University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 28, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Enrollment
110th of 1,269
192 · median 35
Started
2020
with 35 others
No phase
186 of 1,545
34 open now
Registered
1,292nd of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 110th largest by enrollment of the 1,269 interventional ones that give a count, is one of 36 that started in 2020, is one of 186 with no phase, and was the 1,292nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 3 Years to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

Music therapy has become a standard palliative care service in many pediatric and adult hospitals; however, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions. This study builds on prior work examining the psychosocial mechanisms of action underlying an Active Music Engagement (AME) intervention, designed to help manage emotional distress and improve positive health outcomes in young children with cancer and parents, by examining its effects on biomarkers of stress and immune function. The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment. Specific aims are to: Aim 1. Establish whether AME lowers child and parent cortisol during ALL treatment. Aim 2. Examine cortisol as a mediator of AME effects on child and parent outcomes during ALL treatment. Aim 3 (exploratory). Examine the dose-response relationship of AME on child and parent cortisol during ALL treatment. Findings will provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function, with direct implications for the evidence-based use of music to improve health.

Read the detailed description

Music therapy has become a standard palliative care service in many pediatric and adult hospitals. However, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions. In addition, few studies have examined dose-response relationships. Cancer treatment is an inherently stressful experience, and a significant number of young children and parents (caregivers) experience persistent, interrelated emotional distress and poor quality of life. Many parents also experience traumatic stress symptoms because of their child's cancer diagnosis and treatment. The investigators previously tested an Active Music Engagement (AME) intervention that uses active music play to diminish stressful attributes of cancer treatment to help manage emotional/traumatic distress experienced by young children (ages 3-8) and parents and improve quality of life. A recent AME trial is examining psychosocial mechanisms of action responsible for change in child/parent outcomes. The current study expands on this work by examining AME's effects on several biomarkers to provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function. The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment. Specific aims are to: 1) establish whether AME lowers child and parent cortisol, 2) examine cortisol as a mediator of AME effects on child and parent outcomes, and 3) examine the dose-response relationship of AME on child and parent cortisol. Child/parent dyads (n=250) will be stratified (by age, site, ALL risk level) and randomized in blocks of four to AME or attention control. Each group will receive one 45-minute session during weekly clinic visits for the duration of ALL consolidation (4 weeks standard risk; 8 weeks high risk). Parents will complete measures at baseline and following the last study session. Child and parent salivary cortisol samples will be taken pre and post-session for the first 4 AME or attention control sessions. Child blood samples will be reserved from routine blood draws prior to sessions 1 and 4 (all participants) and session 8 (high risk participants). Linear mixed models will be used to estimate AME's effect on child and parent cortisol. Examining child and parent cortisol as mediators of AME effects on child and parent outcomes will be performed in an ANCOVA setting, fitting the appropriate mediation models using MPlus and then testing indirect effects using the percentile bootstrap approach to estimate the indirect effect. Graphical plots and non-linear repeated measures models will be used to examine the dose-response relationship of AME on child and parent cortisol.

03

Conditions studied

  • Acute Lymphoblastic Leukemia, Pediatric
  • Pediatric Cancer
04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child is 3 - 8 years of age at time of enrollment
  • Child has diagnosis of standard or high risk B- or T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LyLy)
  • Child is currently receiving induction therapy
  • One parent (>18 years of age) can be present for all sessions.

Exclusion criteria

Exclusion Criteria:

  • Child has Ph+ ALL,
  • Child has Cushing disease,
  • Child is taking medication for asthma and/or has asthma that is not well controlled,
  • The parent does not speak English, or
  • The child has a significant cognitive impairment that might hinder participation (determination made in consultation with attending physician, oncologist, and parents).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Active Music Engagement

    See intervention description.

    Behavioral: Active Music Engagement

  • Active comparator
    Audio Storybooks

    See intervention description.

    Behavioral: Audio Storybooks

Interventions

  • BehavioralActive Music Engagement

    Weekly 30-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.

  • BehavioralAudio Storybooks

    Weekly 30-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.

06

What researchers measure

Primary outcomes

  1. Percent Change in Child Stress (Salivary Cortisol)

    The primary outcome will be the percent change in child salivary cortisol from pre- to post-session at each session number (2, 3 and 4) for each child. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with child as a subject effect. Predictors will include session number (2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.

    Time frame: Pre/Post-Sessions 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).

  2. Percent Change in Parent Stress (Salivary Cortisol)

    The primary outcome will be the percent change in parent salivary cortisol from pre- to post-session at each session number (1, 2, 3 and 4) for each parent. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with parent as a subject effect. Predictors will include session number (1, 2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.

    Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).

  3. Change in Child Immune Function - IL-10 Cytokine

    IL-10 is a cytokine broadly produced by many cells in the immune system. It is a feedback regulator known to limit inflammatory responses. IL-10 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (6.9 pg/mL) was assigned.

    Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)

  4. Change in Child Immune Function - IL-13 Cytokine

    IL-13 is a cytokine that helps drive type 2 responses allowing the body to defend against parasites by activating mast cells, basophils, and eosinophils. IL-13 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.9 pg/mL) was assigned.

    Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)

  5. Change in Child Immune Function - IL-6 Cytokine

    IL- 6 is a pro-inflammatory cytokine that activates the JAK/STAT pathway. IL-6 is part of defense against infections; however, overproduction can lead to severe complications. IL-6 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.4 pg/mL) was assigned.

    Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)

  6. Change in Child Immune Function - TNF-α Cytokine

    TNF-α is a pro-inflammatory cytokine known activate innate and adaptive immune responses. The chemical signals from TNF will affect the body's response to infection. TNF-α was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (26.7 pg/mL) was assigned.

    Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)

  7. Percent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)

    Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child mental health through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. CHQ mental health scores range from 16 - 80 with higher scores indicating better mental health. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

    Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)

  8. Percent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in Children

    Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child quality of life through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. KINDLR quality of life scores range from 20 - 100 with higher scores indicating better quality of life. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

    Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)

  9. Percent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)

    Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's mood disturbance through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. POMS-SF scores range from -32-116 with higher scores indicating greater mood disturbance. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

    Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)

  10. Percent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)

    Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's traumatic stress symptoms through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IES-R scores range from 0-12 with higher scores indicating greater traumatic stress symptoms. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

    Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)

  11. Percent Change in Salivary Cortisol and Index of Well-being

    Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's well-being through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IWB scores range from 9-63 with higher scores indicating greater well-being. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

    Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneActive Music Engagement - ChildrenActive Music Engagement - ParentsAudio Storybooks - ChildrenAudio Storybooks - Parents
Started46464747
Completed44444444
Not completed2233

Outcome measures

PrimaryPercent Change in Child Stress (Salivary Cortisol)

The primary outcome will be the percent change in child salivary cortisol from pre- to post-session at each session number (2, 3 and 4) for each child. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with child as a subject effect. Predictors will include session number (2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.

Time frame:
Pre/Post-Sessions 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
Reported as:
Least squares mean · pre to post ln(%) change across sessions
Percent Change in Child Stress (Salivary Cortisol)
pre to post ln(%) change across sessionsActive Music Engagement (Child)Audio Storybooks (Child)
Percent Change in Child Stress (Salivary Cortisol)-33.28 ± 6.95-7.82 ± 8.12
Statistical analysis
  • Active Music Engagement (Child) vs Audio Storybooks (Child) · Mixed Models Analysis · p = 0.0173 · Mean difference (final values): 25.47 · 95% CI 4.63 to 46.30Intervention group effect was adjusted for session number (2, 3, 4) and patient risk level (high, standard).
PrimaryPercent Change in Parent Stress (Salivary Cortisol)

The primary outcome will be the percent change in parent salivary cortisol from pre- to post-session at each session number (1, 2, 3 and 4) for each parent. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with parent as a subject effect. Predictors will include session number (1, 2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.

Time frame:
Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
Reported as:
Least squares mean · pre to post ln(%) change across sessions
Percent Change in Parent Stress (Salivary Cortisol)
pre to post ln(%) change across sessionsActive Music Engagement (Parent)Audio Storybooks (Parent)
Percent Change in Parent Stress (Salivary Cortisol)-33.71 ± 5.42-15.33 ± 5.60
Statistical analysis
  • Active Music Engagement (Parent) vs Audio Storybooks (Parent) · Mixed Models Analysis · p = 0.0178 · Mean difference (final values): 18.38 · 95% CI 3.25 to 33.52Intervention group effect was adjusted for session number (1, 2, 3, 4) and patient risk level (high, standard).
PrimaryChange in Child Immune Function - IL-10 Cytokine

IL-10 is a cytokine broadly produced by many cells in the immune system. It is a feedback regulator known to limit inflammatory responses. IL-10 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (6.9 pg/mL) was assigned.

Time frame:
Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Reported as:
Mean · pg/mL
Change in Child Immune Function - IL-10 Cytokine
pg/mLActive Music Engagement (Child)Audio Storybooks (Child)
Pre-session 16.9 ± 0.07.4 ± 2.6
Pre-session 47.1 ± 1.16.9 ± 0.5
Pre-session 86.9 ± 0.06.9 ± 0.0
PrimaryChange in Child Immune Function - IL-13 Cytokine

IL-13 is a cytokine that helps drive type 2 responses allowing the body to defend against parasites by activating mast cells, basophils, and eosinophils. IL-13 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.9 pg/mL) was assigned.

Time frame:
Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Reported as:
Mean · pg/mL
Change in Child Immune Function - IL-13 Cytokine
pg/mLActive Music Engagement (Child)Audio Storybooks (Child)
Pre-session 11.9 ± 0.11.9 ± 0.0
Pre-session 41.9 ± 0.01.9 ± 0.0
Pre-session 81.9 ± 0.01.9 ± 0.0
PrimaryChange in Child Immune Function - IL-6 Cytokine

IL- 6 is a pro-inflammatory cytokine that activates the JAK/STAT pathway. IL-6 is part of defense against infections; however, overproduction can lead to severe complications. IL-6 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.4 pg/mL) was assigned.

Time frame:
Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Reported as:
Mean · pg/mL
Change in Child Immune Function - IL-6 Cytokine
pg/mLActive Music Engagement (Child)Audio Storybooks (Child)
Pre-session 11.5 ± 0.11.5 ± 0.1
Pre-session 41.9 ± 2.16.5 ± 29.8
Pre-session 81.6 ± 0.51.9 ± 1.5
PrimaryChange in Child Immune Function - TNF-α Cytokine

TNF-α is a pro-inflammatory cytokine known activate innate and adaptive immune responses. The chemical signals from TNF will affect the body's response to infection. TNF-α was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (26.7 pg/mL) was assigned.

Time frame:
Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Reported as:
Mean · pg/mL
Change in Child Immune Function - TNF-α Cytokine
pg/mLActive Music Engagement (Child)Audio Storybooks (Child)
Pre-session 127.6 ± 5.327.7 ± 4.9
Pre-session 427.3 ± 4.230.2 ± 20.1
Pre-session 826.7 ± 0.026.7 ± 0.0
PrimaryPercent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)

Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child mental health through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. CHQ mental health scores range from 16 - 80 with higher scores indicating better mental health. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

Time frame:
Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Reported as:
Mean · score on a scale
Percent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)
score on a scaleActive Music EngagementAudio Storybooks
Baseline41.9 ± 16.943.3 ± 14.6
Follow-up27.4 ± 14.028.6 ± 15.4
Statistical analysis
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.840 · Standardized coefficient from sem: -0.006 · 95% CI -0.067 to 0.054
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.325 · Standardized coefficient from sem: -0.029 · 95% CI -0.086 to 0.028
PrimaryPercent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in Children

Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child quality of life through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. KINDLR quality of life scores range from 20 - 100 with higher scores indicating better quality of life. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

Time frame:
Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Reported as:
Mean · score on a scale
Percent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in Children
score on a scaleActive Music EngagementAudio Storybooks
Baseline57.4 ± 18.156.3 ± 17.7
Follow-up71.0 ± 14.970.7 ± 12.8
Statistical analysis
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.214 · Standardized coefficient from sem: 0.048 · 95% CI -0.028 to 0.123
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.494 · Standardized coefficient from sem: 0.023 · 95% CI -0.043 to 0.088
PrimaryPercent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)

Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's mood disturbance through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. POMS-SF scores range from -32-116 with higher scores indicating greater mood disturbance. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

Time frame:
Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Reported as:
Mean · score on a scale
Percent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)
score on a scaleActive Music EngagementAudio Storybooks
Baseline53.4 ± 23.865.4 ± 27.4
Follow-up42.8 ± 22.150.2 ± 26.1
Statistical analysis
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.582 · Standardized coefficient from sem: 0.013 · 95% CI -0.033 to 0.059
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.222 · Standardized coefficient from sem: -0.037 · 95% CI -0.096 to 0.022
PrimaryPercent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)

Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's traumatic stress symptoms through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IES-R scores range from 0-12 with higher scores indicating greater traumatic stress symptoms. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

Time frame:
Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Reported as:
Mean · score on a scale
Percent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)
score on a scaleActive Music EngagementAudio Storybooks
Baseline3.4 ± 2.04.0 ± 2.1
Follow-up2.5 ± 1.93.2 ± 1.9
Statistical analysis
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.725 · Standardized coefficient from sem: 0.010 · 95% CI -0.047 to 0.068
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.153 · Standardized coefficient from sem: -0.045 · 95% CI -0.106 to 0.017
PrimaryPercent Change in Salivary Cortisol and Index of Well-being

Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's well-being through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IWB scores range from 9-63 with higher scores indicating greater well-being. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.

Time frame:
Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Reported as:
Mean · score on a scale
Percent Change in Salivary Cortisol and Index of Well-being
score on a scaleActive Music EngagementAudio Storybooks
Baseline47.4 ± 10.145.3 ± 9.6
Follow-up49.8 ± 10.445.7 ± 9.6
Statistical analysis
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.869 · Standardized coefficient from sem: -0.004 · 95% CI -0.055 to 0.047
  • Active Music Engagement vs Audio Storybooks · Structural equation modeling · p = 0.610 · Standardized coefficient from sem: 0.013 · 95% CI -0.038 to 0.065

Adverse events

Collected over from randomization until end of follow-up, up to 14 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Music Engagement - Child0/46 (0%)0/46 (0%)0/46 (0%)
Active Music Engagement - Parent0/46 (0%)0/46 (0%)1/46 (2.2%)
Audio Storybooks - Child0/47 (0%)0/47 (0%)1/47 (2.1%)
Audio Storybooks - Parent0/47 (0%)0/47 (0%)0/47 (0%)
Most frequent other events
Most frequent other events
EventActive Music Engagement - ChildActive Music Engagement - ParentAudio Storybooks - ChildAudio Storybooks - Parent
Parent stressSocial circumstances0/461/460/470/47
Child emotional dysregulationSocial circumstances0/460/461/470/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Active Music Engagement (Child)Active Music Engagement (Parent)Audio Storybooks (Child)Audio Storybooks (Parent)Total
Mean4.5 ± 1.435.2 ± 5.54.4 ± 1.535.1 ± 5.319.8 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)Active Music Engagement (Child)Active Music Engagement (Parent)Audio Storybooks (Child)Audio Storybooks (Parent)Total
Female19372238116
Male27924868
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Music Engagement (Child)Active Music Engagement (Parent)Audio Storybooks (Child)Audio Storybooks (Parent)Total
Hispanic or Latino765624
Not Hispanic or Latino38394040157
Unknown or Not Reported11215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Music Engagement (Child)Active Music Engagement (Parent)Audio Storybooks (Child)Audio Storybooks (Parent)Total
American Indian or Alaska Native00426
Asian223411
Native Hawaiian or Other Pacific Islander00000
Black or African American442313
White35353636142
More than one race00000
Unknown or Not Reported552214
08

Study locations

4 sites
  • UCSF Benioff Children's Hospital
    Oakland, California 94609, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
09

References and documents

Publications

  • Robb SL, Clair AA, Watanabe M, Monahan PO, Azzouz F, Stouffer JW, Ebberts A, Darsie E, Whitmer C, Walker J, Nelson K, Hanson-Abromeit D, Lane D, Hannan A. A non-randomized [corrected] controlled trial of the active music engagement (AME) intervention on children with cancer. Psychooncology. 2008 Jul;17(7):699-708. doi: 10.1002/pon.1301. PubMed 18033724 ↗
  • Robb SL, Haase JE, Perkins SM, Haut PR, Henley AK, Knafl KA, Tong Y. Pilot Randomized Trial of Active Music Engagement Intervention Parent Delivery for Young Children With Cancer. J Pediatr Psychol. 2017 Mar 1;42(2):208-219. doi: 10.1093/jpepsy/jsw050. PubMed 27289068 ↗
  • Robb SL. The effect of therapeutic music interventions on the behavior of hospitalized children in isolation: developing a contextual support model of music therapy. J Music Ther. 2000 Summer;37(2):118-46. doi: 10.1093/jmt/37.2.118. PubMed 10932125 ↗
  • MacLean JA, Stegenga KA, Henley AK, Robb SL. Implementing NIH Behavior Change Consortium Treatment Fidelity Recommendations in a Multi-Site Randomized Controlled Trial of an Active Music Engagement Intervention for Young Children with Cancer and Parents. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221140491. doi: 10.1177/15347354221140491. PubMed 36510388 ↗
  • Robb SL, Russ KA, Holochwost SJ, Stegenga K, Perkins SM, Jacob SA, Henley AK, MacLean JA. Protocol and biomarker strategy for a multi-site randomized controlled trial examining biological mechanisms and dosing of active music engagement in children with acute lymphoblastic leukemia and lymphoma and parents. BMC Complement Med Ther. 2023 Mar 27;23(1):90. doi: 10.1186/s12906-023-03909-w. PubMed 36973774 ↗
  • Holochwost SJ, Harman E, Stegenga K, Jacob SA, Robb SL. Who benefits from active music engagement during cancer treatment? Associations of sociodemographic characteristics and risk factors with moderators of intervention effects. Front Psychol. 2025 Jul 29;16:1550051. doi: 10.3389/fpsyg.2025.1550051. eCollection 2025. PubMed 40799339 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Apr 2025, 56 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 56 months is above that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2020
First posted
May 22, 2020
StartActual
Aug 7, 2020
Primary completionActual
Apr 11, 2025
CompletionActual
Apr 11, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Primary outcomes
6 edited, 5 added, 1 removed
What changed in the outcomes
  • EditedPercent Change in Child and Parent Stress (Salivary Cortisol)Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 45 min. duration). → Pre/Post-Sessions 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
  • EditedPercent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants) → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
  • EditedPercent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in ChildrenTime frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
  • EditedPercent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
  • EditedPercent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
  • EditedPercent Change in Salivary Cortisol and Index of Well-beingTime frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants) → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
  • AddedPercent Change in Parent Stress (Salivary Cortisol)Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
  • AddedChange in Child Immune Function - IL-10 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
  • AddedChange in Child Immune Function - IL-13 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
  • AddedChange in Child Immune Function - IL-6 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
  • AddedChange in Child Immune Function - TNF-α CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
  • RemovedChange in Immunomodulatory Cytokines (children only) (blood)Time frame: Pre-Session Week 1 and Week 4 (all child participants); and Pre-Session Week 8 (only high risk child participants).
Oct 28, 2026
Documents
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 6 edited, 5 added, 1 removed
    What changed in the outcomes
    • EditedPercent Change in Child and Parent Stress (Salivary Cortisol)Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 45 min. duration). → Pre/Post-Sessions 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
    • EditedPercent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants) → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
    • EditedPercent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in ChildrenTime frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
    • EditedPercent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
    • EditedPercent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)Time frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants). → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
    • EditedPercent Change in Salivary Cortisol and Index of Well-beingTime frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants) → Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
    • AddedPercent Change in Parent Stress (Salivary Cortisol)Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
    • AddedChange in Child Immune Function - IL-10 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
    • AddedChange in Child Immune Function - IL-13 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
    • AddedChange in Child Immune Function - IL-6 CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
    • AddedChange in Child Immune Function - TNF-α CytokineTime frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
    • RemovedChange in Immunomodulatory Cytokines (children only) (blood)Time frame: Pre-Session Week 1 and Week 4 (all child participants); and Pre-Session Week 8 (only high risk child participants).
    + 4 other changes: verification date, responsible party, arm descriptions and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04400071
Lead sponsor
Indiana University
Collaborators
Children's Mercy Hospital Kansas City, Ann & Robert H Lurie Children's Hospital of Chicago, National Institute of Nursing Research (NINR), James Whitcomb Riley Hospital for Children, UCSF Benioff Children's Hospital Oakland
Responsible party
Sheri Robb (Walther Professor of Supportive Oncology, Indiana University) — Principal investigator
First posted
May 22, 2020
Start date
Aug 7, 2020
Primary completion
Apr 11, 2025
Completion
Apr 11, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Sheri L Robb, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion